<DOC>
	<DOCNO>NCT01103388</DOCNO>
	<brief_summary>The goal clinical research see Rituxan ( rituximab ) therapy give high dose chemotherapy transplant patient stem cell prevent delay return lymphoma .</brief_summary>
	<brief_title>Rituximab Maintenance After Autologous Transplantation</brief_title>
	<detailed_description>Rituxan mouse antibody change make similar human antibody . Antibodies proteins protect body foreign invader , bacteria virus , bind substance call antigen . Rituxan work bind protein , call CD20 protein ( found surface normal cancerous B-lymphocytes ) . This binding may help destroy B-lymphocytes . Before study begin , physical exam , routine blood test ( 1-2 tablespoon ) , urine test . Women able child must negative blood pregnancy test . You also chest x-ray ECG ( test measure electrical activity heart ) . The status lymphoma evaluate bone marrow biopsy . To collect bone marrow sample , area hip chest bone numb anesthetic small amount bone marrow withdrawn large needle . CT scan gallium PET scan perform . If lymphoma area body additional test may need determine treat physician . Tests evaluate status lymphoma repeat cycle chemotherapy . If white count low may need injection NeupogenTM ( growth factor ) daily till white blood cell count high enough start next round treatment . You randomly assign ( toss coin ) one two treatment group . Participants one group receive rituximab . Participants group receive rituximab . There equal chance assign either group . Treatment start 5-6 month stem cell transplant . If assign rituximab group , receive total 4 cycle treatment . Each cycle give 6 month apart . Each cycle make 4 dos rituximab give week 4 week . If disease return intolerable side effect occur treatment , take study . You may still able receive rituximab outside study treat physician decide okay . Treatment give outpatient basis . The treatment give M. D. Anderson local cancer doctor . Patients assign rituximab arm must willing get first third cycle ( 4 dos ) M. D. Anderson , local physician unable draw ship sample central laboratory rituximab level . Blood drawn ( approximately one teaspoon ) first fourth dose second third dose two treatment cycle . The treatment give vein period several hour . Participants easily accessible vein may get treatment temporary needle place vein treatment . For participant easily accessible vein , central venous catheter ( long plastic tube - CVL ) place big vein arm chest . Participants receive rituximab follow every 6 month M. D. Anderson standard care . All participant ( even receive rituximab ) return M. D. Anderson every 6 month period 3 year ( date enrollment ) lymphoma evaluate . The status lymphoma evaluate blood test ( 1-2 tablespoon ) , CT scan , PET Gallium scan bone marrow biopsy . This investigational study . Rituximab approve FDA . About 90 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Patients diffuse large B cell nonHodgkin 's lymphoma 56 month status post autologous stem cell transplant CR . Patients positive ( 14 ; 18 ) PCR BCL2 Southern blot eligible provide disease present . 2 . Absolute neutrophil count ( ANC ) &gt; 1500/mm3 independent growth factor support 3 . No evidence symptomatic cardiac pulmonary disease 4 . Platelet count &gt; 75,000 mm3 5 . Zubrod performance status 2 less . 6 . Negative pregnancy test patient `` child bearing potential '' 1 . Uncontrolled active infection 2 . Severe concomitant medical psychiatric illness 3 . Serum bilirubin &gt; 2.0 mg/dl 4 ) Transaminases &gt; 2xULN 5 ) Serum creatinine &gt; 2.0 mg/dl</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>High dose chemotherapy</keyword>
	<keyword>Autologous transplantation</keyword>
	<keyword>Autologous stem cell transplant</keyword>
	<keyword>ASCT</keyword>
</DOC>